NOTICE: Due to the current coronavirus pandemic, please check with the event organiser to confirm any changes to scheduling. Please click here to see the UK Government's response and guidance to the coronavirus (COVID-19).

Loading Events
This event has passed.

Join this event on 22nd March 2022 for the online launch of the InSilicoUK network, co-created with the Royal Academy of Engineering, the British Standards Institute, the Association of British HealthTech Industries, the Association of the British Pharmaceutical Industry, techUK and Avicenna Alliance.

We are bringing together members from academia, industry, regulatory and notified bodies, innovators, technology providers, policy-makers and funders to learn about the transformational prospects of In Silico Trials.

Virtual or “in silico” trials are clinical trials performed in virtual populations via computer modelling and simulation. Computational modelling and simulation (CM&S) are omnipresent across industry sectors underpinned by engineering and science (e.g., automotive, aerospace and microelectronics). Surprisingly, this is seen less in pharma and medtech innovation and regulations. But this might be about to change…

Innovate UK KTN is launching a new UK-wide network, ‘InSilicoUK’,  bringing together a community to deliver an ecosystem for innovation and regulatory science  of medical products that parallels the UK’s ambition to be a “science superpower”.

CM&S promises to become a valid source of scientific evidence on product safety and efficacy that balances the desire for certainty about their performance and risks with limiting current delays in patient access to lifesaving treatments. In silico product design, evaluation and trialling can derisk innovations, cut down R&D costs, and minimise subsequent financial pressures on healthcare systems.

The UK has a world class and vibrant industrial fabric in life sciences, pharmaceuticals and health technologies. The government has recognised the importance of regulatory reform to bolster innovation and economic growth in these sectors. This initiative will identify barriers and enablers for faster adoption of in silico methods throughout the product life cycle, from research and innovation through to standards and regulations.

This industry-led launch event highlights the crucial importance of regulatory science and innovation for the UK economy, its  international dimension, and the key role of standards and regulators.

We are pleased to announce that Indro Mukerjee, CEO of Innovate UK, will be joining this special event as a keynote speaker as well as a selected range of high-profile speakers. We also hope to be joined by the Science Minister, Minister George Freeman, for part of the event. Minister Freeman will set out how virtual clinical trials can help contribute to the UK’s Science Superpower ambitions, driving our progress towards becoming an Innovation Nation.


  • Welcome and Introduction
  • Keynote speeches
  • In Silico Trials: what are they and why a UK Roadmap?
  • Panel of Industry Leaders on unlocking the benefits and adoption of in silico regulatory evidence in the UK
  • Standardisation and Regulations Panel: on regulations, standards and international harmonisation to catalyse adoption of modeling and simulation
  • An open platform to ask questions, identify  barriers and suggest enablers for adoption of in silico trials in innovation and regulations

Who should attend?

This online event is public and open to all. However, we strongly encourage the In Silico trials industry stakeholders, academics, clinicians, and regulators to attend this event.